Treat Seizure – Kepplah Fri, 14 Jan 2022 22:00:00 +0000 en-US hourly 1 Treat Seizure – Kepplah 32 32 Marinus Pharmaceuticals Announces Incentive Grants Under Nasdaq Listing Rule 5635(C)(4) Fri, 14 Jan 2022 22:00:00 +0000

RADNOR, Pa.–(BUSINESS WIRE)–Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to developing innovative therapies to treat seizure disorders, today announced incentive awards for five new employees. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 42,810 common shares (the “Common Shares”) and the grant of units of shares restricted to purchase and a total of 10,800 shares as material incentives for employees entering the employment of the Company pursuant to Nasdaq listing rule 5635(c)(4).

These stock option grants have an exercise price of $11.11 per share, which is equal to the closing price of common stock on January 11, 2022 (grant date of these stock options). of shares). All stock options will vest and become exercisable on 25% of the underlying shares on the first anniversary of the relevant employee’s start date, and will vest and be exercisable on the 75% underlying shares of Common Stock in 36 equal monthly installments thereafter on each monthly anniversary, subject to the affected employee’s continued employment with Marinus on such vesting dates. These RSUs vest in full on the first anniversary of the employee’s date of employment. The stock options and restricted stock units were granted as an incentive to each employee entering the service of Marinus pursuant to Nasdaq listing rule 5635(c)(4) and are subject to the terms and conditions of the applicable award agreement. covering this grant.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapies to treat seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that act on a well-characterized target in the brain known to have anti-epileptic, anti-depressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach for adult and pediatric patient populations in acute and chronic care settings. For more information, visit

Forward-looking statements

To the extent that the statements in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting management’s current beliefs and expectations made pursuant to the provisions of the Private Safe Harbor. Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “expect”, “anticipate”, “estimate”, “intend”, “believe” and similar expressions (as than other words or phrases that refer to future events, conditions or circumstances) are intended to identify forward-looking statements. The forward-looking statements contained in this press release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements. . Marinus assumes no obligation to update or revise any forward-looking statements. For a more detailed description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business generally, see the documents filed by Marinus with the Securities and Exchange Commission.

Tips on Cannabis Use and Investing for Fed Employees (Newsletter: January 11, 2022) Tue, 11 Jan 2022 11:30:47 +0000

KY’s medical cannabis bill tabled; MS Senator Brings Hemp to Government Marijuana Meeting; California Spends $ 100 Million on Marijuana and Cannabis Grants for Cities

Subscribe to receive the Marijuana Moment newsletter delivered to your inbox every morning of the week. It’s the best way to find out which cannabis stories are shaping the day.

Your support makes Marijuana Moment possible…

Free to read (but not free to produce)! We take pride in our newsletter and the reports we publish on Marijuana Moment, and we are happy to provide them for free. But it takes a lot of work and resources to get there.

  • Matt W.: “I got involved because I appreciate the news and information you provide and want to see it continue.”

If you enjoy Marijuana Moment, invest in our success on Patreon so that we can expand our coverage and more readers can benefit:


Anti drug Senator Charles Grassley (R-IA) has helped a church in Iowa that wants to incorporate psychedelic ayahuasca into its ceremonies – the Healing Church of Iowaska – with legal battles against the Drug Enforcement Administration and the Internal Revenue Service.

A Kentucky Republican Representative introduced a medical marijuana bill that has been revised from previous drafts in an effort to gain support – or at least suppress hostile opposition – from legislative leaders so that it can be passed This year.

A senator from mississippi brought hemp to a meeting with Gov. Tate Reeves (R) to help allay the governor’s concerns about the limits on medical marijuana possession.

  • “I took samples to show him what an ounce looks like, what 3.5 grams actually looks like.”

california regulators provided $ 100 million in funding to help local governments develop the legal marijuana market by processing business licenses.


A federal judge dismissed a racial discrimination lawsuit by a Washington state marijuana dispensary against federal and state officials.

Representative Dave Joyce (R-OH) criticized Democratic leaders for failing to advance cannabis reform legislation.

Representative Nancy Mace (R-SC) wrote a letter from the Wall Street Journal to the editor about his marijuana legalization bill.

Florida Democratic Senate Candidate Allen Ellison tweeted: “Not only should we legalize cannabis across the country, we should tax its sale and pay for higher education.”

Kentucky Democratic Candidate for Congress Guillaume Compton tweeted, “Besides the income we can generate by legalizing marijuana, we shouldn’t send someone to jail for marijuana. In Congress, I will fight to legalize marijuana nationwide.


from Rhode Island The Speaker of the House said a new marijuana legalization bill is expected to be released within the next 30 to 45 days.

from New Jersey The Senate Speaker has said he does not believe home growing marijuana will be legalized “anytime soon.”

that of South Carolina The Senate Majority Leader indicated that a medical cannabis bill would soon be considered, saying: “I don’t know where the votes will be, but we all agree it’s time to have a debate and to move on. ” And another senator said he expects the legislation to be one of the first raised in the new session.

the Wisconsin The House State Affairs Committee has approved a draft law on the regulation of kratom.

Mississippi lawmakers are expected to consider a medical cannabis bill this week. One senator wants pharmacists to be involved in the distribution of marijuana.

the Virginia the Legislative Assembly’s Cannabis Oversight Committee will meet on Monday.

Kansas House Democrats tweeted, “House Democrats want Kansans like YOU to decide whether Kansas should expand Medicaid and legalize marijuana.” Contact your #ksleg-legislator TODAY and tell them you want to vote on issues that affect your life and health.

A Florida The senator introduced a bill to legalize marijuana and related tax legislation.

A Indiana representative filed a medical cannabis bill.

A Maryland The senator tweeted: “Legalizing marijuana is not about facilitating access to personal indulgence, but about creating equality.”

the Illinois The Supreme Court is being asked by a marijuana company to let regulators name the winners of the new artisanal producer licenses.

New York regulators have tabled proposed rules on cannabinoid hemp. Separately, the Department of Agriculture and Markets is looking for Certified Hemp Sampling Agents.

the Utah The Peace Officer Standards & Training Council voted that cadets who apply to be emergency dispatchers do not have to have a waiting period if they have used marijuana in a location where it is legal.

Ohio regulators have received nine petitions to add new eligibility requirements for medical cannabis.

Oregon regulators are investigating interest in accessing psilocybin services and related issues.

Vermont regulators will look at the marijuana issues on Monday.

the Washington state The Cannabis Science Working Group will meet on Monday.

Marijuana Moment is already following more than 900 cannabis, psychedelic, and drug bills in state legislatures and in Congress this year. Patreon supporters pledging at least $ 25 / month have access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our Marijuana Bill Tracker and become a Patreon supporter to access it.


the Kent, Ohio The city council proposes to include a measure to decriminalize marijuana on the November ballot.

Long beach, california the mayor tweeted, “In Long Beach, we legalized cannabis before the state. We created a regulatory framework and taxed products and production. It’s time to legalize weed across the country.

Oakland, California Officials will discuss loan and grant programs for cannabis capital companies on Tuesday.


Appointment for first dose COVID vaccinations in Quebec, Canada rose after the government announced shots would be required to enter marijuana dispensaries and liquor stores.

the Australian The government is funding clinical trials of psychotherapy assisted by psilocybin, CBD, DMT and MDMA to treat debilitating mental illnesses.


A study found that “two years after legalization in Canada, the price of dried flowers from legal sources has declined, along with a higher percentage of consumers. buy from legal sources only after a year.

One study suggested that “the use of MDMA / ecstasy and psilocybin is associated with less risk of depression. “


the American Medical Association said the expansion of medical marijuana research will be a topic of discussion at his conference next month.

the Kentucky Democratic Party tweeted: “Democrats get to work every day this session, committed to fighting for you. Healthcare, Voting Rights, Universal Pre-K, Medical Marijuana and more: @GovAndyBeshear, @KYSenateDems and @KYHouseDems prioritize issues that matter to Kentuckians. “


Columbia Care Inc. initiates a solicitation of consents from the Noteholders.

Ayr Well-being takes stock of its share buyback program.

Swade Cannabis workers in St. Louis, Missouri, seek to organize a union.


Director Kevin smith posted on his daughter at a marijuana dispensary.

Make sure to subscribe to receive Marijuana Moment Daily Shipment to your inbox.

Marijuana Moment is made possible by the support of readers. If you rely on our Cannabis Advocacy Journalism to stay informed, please consider a monthly Patreon engagement.

Lamotrigine linked to lower risk of death in post-stroke epilepsy Sat, 08 Jan 2022 01:36:04 +0000

Among the anti-epileptic drugs (MAs) used as monotherapy in post-stroke epilepsy (PSE), lamotrigine is associated with the lowest risk of mortality and valproic acid is associated with the highest risk, new research suggests.

Investigators evaluated more than 2,500 patients, most in their late sixties, using carbamazepine as a comparator.

The results showed that valproic acid, phenytoin and oxcarbazepine had a significantly higher risk of death from all causes and cardiovascular compared to carbamazepine, while lamotrigine had a significantly lower risk for both side effects. . Although levetiracetam was associated with a lower risk of cardiovascular death, it showed no significant difference in overall mortality.

“We found differences in survival between patients [with PSE] treated with different antiepileptic drugs, “said lead author David Larsson, MD, Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden. Medscape Medical News.

“The take-home message for practicing clinicians is that people with epilepsy after stroke are a vulnerable group who benefit from tailor-made treatment, and the choice of antiepileptic drugs depends on many factors,” said Larsson.

However, “at the group level, it seems reasonable to avoid drugs that may interfere with other drugs used to prevent stroke and heart disease,” he added.

The results were published online Dec. 13 in JAMA Neurology.

Possible drug interaction?

“Observational studies have linked epilepsy with increased mortality,” Larsson noted.

“There have been concerns that enzyme-inducing antiepileptic drugs, such as carbamazepine, may interact with drugs used in stroke prevention, possibly leading to an increased risk of cardiovascular events,” he said.

The researchers therefore “aimed to determine whether mortality varied with different antiepileptic drugs.”

Investigators relied on data from four large population-based registries including all adults in Sweden who had an acute stroke from July 1, 2005 to December 31, 2010, and with subsequent onset of epilepsy before December 31, 2015 ( n = 2577; 54% male; mean age: 78).

The median time from stroke to first seizure-related diagnostic code was just under one year (347 days). The median length of follow-up from start of treatment to death or censorship at the end of the study was 2.2 years.

Covariates included demographic characteristics, stroke characteristics, lifestyle, activities of daily living, and pre-stroke smoking habits. It also included comorbidities such as hypertension, diabetes, and atrial fibrillation and medications such as statins and antidepressants.

Of the patients, 82% had suffered an acute ischemic stroke, most (70%) had hypertension, and most (82%) had lived without assistance prior to their stroke. After the stroke, only 44% were able to live without assistance.

The researchers chose carbamazepine as the reference drug because it is frequently prescribed and has enzyme-inducing properties.

Improved metabolism

During the study period, 1,550 deaths occurred. The highest 3-year survival rate was associated with lamotrigine and the lowest with valproic acid and phenytoin (Table 1).

Table 1. 3-year survival rate compared to carbamazepine

Medication Survival rate (95% CI)
Lamotrigine .62 (.56 – .67)
Levetiracetam .55 (.49 – .61)
Oxcarbazepine .54 (0.39 – .68)
Carbamazepine .53 (.50 – .56)
Valproic acid 0.34 (0.30 – 0.39)
Phenytoin .32 (0.21 – .43)
CI = confidence interval

When the researchers analyzed the 5-year survival rate, the differences between lamotrigine, valproic acid, and carbamazepine remained statistically significant.

Lamotrigine also had the lowest risk of mortality compared to carbamazepine, followed by levetiracetam, while phenytoin, oxcarbazepine and valproic acid had the highest risk (Table 2).

Table 2. Adjusted risk ratio for all-cause mortality compared to carbamazepine

Medication Adjusted HR (95% CI)
Lamotrigine .72 (0.60 – .86)
Levetiracetam .96 (0.80 – 1.15)
Phenytoin 1.16 (0.88 – 1.51
Oxcarbazepine 1.16 (0.81 – 1.66)
Valproic acid 1.40 (1.23 – 1.59)
HR = risk ratio

The underlying cause of death in more than half of the cases (63%) was cardiovascular disease. Compared with carbamazepine, lamotrigine and valproic acid were both associated with a significantly lower and higher risk of cardiovascular death, respectively (Table 3).

Table 3. Risk of cardiovascular death compared to carbamazepine

Medication Adjusted HR (95% CI)
Lamotrigine .76 (0.61 – .95)
Levetiracetam 0.77 (0.60 – 0.99)
Phenytoin 1.02 (0.71 – 1.47)
Oxcarbazepine 0.71 (0.42 – 1.18)
Valproic acid 1.40 (1.19 – 1.64)

A range of sensitivity analyzes “suggested that the differences were less likely to be explained by the severity of the epilepsy or variations in prescribing patterns over time,” Larsson said.

“Our results raise the possibility that specific ASMs influence the risk of cardiovascular and all-cause death, although our study design does not allow causal inference,” the investigators write.

Nevertheless, they note that the altered vascular risk may explain the results. In particular, enzyme-inducing ASMs (carbamazepine and phenytoin) improve the metabolism of drugs commonly used in secondary prevention after stroke, in particular anticoagulants, calcium channel blockers and statins.

The researchers add that the United States Food and Drug Administration has issued a safety communication regarding the potential proarrhythmic effects of lamotrigine, and the International League Against Epilepsy has also issued recommendations on cardiac risk with lamotrigine.

However, “our real-world investigation does not suggest that lamotrigine

is expected to present a particular risk to patients with PSE at the group level, ”the investigators write.

“Think twice”

Comment for Medscape Medical News, RPW Rouhl, MD, PhD, neurologist at Maastricht University Medical Center, Academic Center for Epileptology Kempenhaeghe / MUMC, The Netherlands, called the study “well done”.

However, it is “difficult to determine why” the anti-epileptic drugs (AEDs) that conferred the lowest risk of death were lamotrigine and levetiracetam, said Rouhl, who was not involved in the research.

He added that the study has “some slight weaknesses that stem from its design.” For example, using the combination of multiple registers “does not lead to case determination,” he noted.

Also, the study participants “probably” had PSE, “but that’s just the combination of the record in this stroke database and the post-epilepsy diagnostic code. ‘stroke that suggests it, “Rouhl said.

In addition, only patients taking monotherapy were included, “while patients with poor response to treatment may require a change in AED or combination therapy with AED, so perhaps the design selected patients with treatable epilepsy that may be more susceptible to the side effects of AED treatments, ”he noted.

Nonetheless, Rouhl called the mortality data “quite convincing”, adding: “while it is not certain whether the effect is entirely specific to patients with post-stroke epilepsy, the effects on mortality are there. for patients in these older patient cohorts. . “

For this reason, “neurologists should think twice before prescribing valproic acid, and possibly other older AEDs, to elderly patients,” Rouhl concluded.

The study was funded by grants from the Swedish State, the Swedish Society of Medicine, the Swedish Society for Medical Research, the Linnea and Josef Carlsson Foundation, the Gothenburg Medical Society and the Magnus Bergvall Foundation. . Larsson and Rouhl did not disclose any relevant financial relationship. Disclosures by other authors are listed in the original article.

JAMA Neurol. Published online December 13, 2021. Summary

For more information on Medscape Neurology, join us on Facebook and Twitter.

Chicago CBP Intercepts Various Illicit Products During FY 21 Wed, 05 Jan 2022 18:19:21 +0000

CHICAGO-CBP’s International Mail Facility (IMF) in O’Hare processes millions of packages a year, however, many packages arriving from overseas contain illegal products. CBP agents work around the clock to ensure that incoming packages are safe, protecting our communities.

The Schedule II opioid, Tapentadol was number one
seized of narcotics this year by the Chicago CBP. Officers seized
a total of 5,624 pounds are narcotics in Chicago.

During fiscal year 2021, which ran from October 1, 2020 to September 30, 2021, CBP officers in Chicago seized 5,624 pounds of narcotics and $ 7.89 million in counterfeit goods.

Chicago’s CBP has seen a 10% increase in drug seizures this year. The main drug seized in Chicago this year was Tapentadol, a Schedule II opioid. This drug came in different doses and was mainly shipped from India, destined for addresses across the United States. CBP seized 2,399 shipments nationwide, an increase of 605% from last year. The second highest seizure in the Chicago MFI was Carisoprodol, a Schedule IV drug used to treat musculoskeletal pain, seizures of this drug increased 105% from last year. CBP seized 2,193 shipments of the drug. These shipments originated mainly from India to the United States. Carisoprodol has serious side effects, including drug addiction and seizures. Psilocybin Mushrooms finished third, with CBP seizing 439 shipments of these magic mushrooms, known for their hallucinogenic effects.

In addition, Chicago’s CBP intercepted 94 shipments of counterfeit goods, with Louis Vuitton handbags, Rolex watches and Gucci handbags being the main items seized. CBP plays a vital role in protecting the economy and the safety and health of consumers, legitimate businesses and the global supply chain.

There are several steps consumers can take to protect themselves while shopping online. Buy products only from reputable retailers and beware of third-party suppliers. Check out seller reviews and verify that there is a valid phone number and address for the seller, in case you have questions about a product’s legitimacy.

“Last year’s foreclosures show the great job our CBP officers are doing here in Chicago,” said LaFonda Sutton-Burke, director of field operations in Chicago. “More and more consumers are using e-commerce at unprecedented levels to purchase items. Buyers should be aware that criminals are prepared to steal your money by claiming that these fake and illegal items are real and / or safe. The buyer must be vigilant and informed.

In addition, CBP agriculture specialists in Chicago issued 2,486 mail interception notices. These seizures largely concerned food products, including meat products, fresh fruits and vegetables. Fresh fruits and vegetables present the obvious risk of carrying pests or diseases that could cause serious epidemics in agricultural crops in the United States. These pests and diseases would otherwise be separated from this continent by the oceans. Animal products such as cold meats can also be dangerous for our agriculture. Although these products have undergone a process of preservation for human consumption (for example, hardening to prevent the growth of bacteria), economically important livestock viruses may in fact be stored in this animal tissue and remain viable longer than in the environment. raw meat. The discarded products can then pave the way for the introduction of this disease into the United States.

CBP also seized 268 shipments containing more than $ 7.38 million in US currency and arrested 117 criminals who were leaving or arriving in O’Hare with outstanding warrants.

“Our highly trained officers are always on the alert for those fleeing the country to avoid prosecution or enter the United States with outstanding warrants,” said Shane Campbell, regional manager of the Port of Chicago. “With the tools at our disposal, we are very good at apprehending wanted criminals.”

The CBP National Fiscal Year numbers are also now available on our website on the application page: CBP Enforcement Statistics Fiscal Year 2022 | United States Customs and Border Protection. For more background, please refer to our press release located here.

CBP operates at ports of entry across the United States and routinely screens incoming international passengers and cargo for narcotics, weapons, and other regulated or prohibited products. CBP strives to serve as the premier law enforcement agency to improve the safety, security and prosperity of the nation through collaboration, innovation and integration.

Ovid Therapeutics Expands Epilepsy Franchise With New KCC2 Activators Mon, 03 Jan 2022 12:15:21 +0000
  • AstraZeneca Exclusive License Adds Unique Candidate and Large Compound Library to Ovid’s Franchise of Potential First-Class Antiepileptic Therapies
  • Collaboration with Dr Stephen Moss, founder of the Tufts Laboratory for Basic and Translational Neuroscience Research, and team of experts in neuropharmacology
  • Transaction is the first business development activity that aims to enhance Ovid’s CNS small molecule and genetic drug portfolio

NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) – Ovid Therapeutics (NASDAQ: OVID), a biopharmaceutical company committed to the development of drugs that transform the lives of people with rare neurological diseases, today announced the signing of an exclusive license agreement with AstraZeneca for an early stage small molecule library targeting the KCC2 transporter, including the lead candidate, OV350. The company seeks to optimize and accelerate the development of these activators of the KCC2 transporter in epilepsies and potentially other neuropathic conditions.

“The KCC2 transporter is an exciting and new target that we believe holds great promise in the treatment of epilepsies,” said Jeremy Levin, D.Phil, MB BChir, CEO of Ovid. “The compounds are a perfect fit for our franchise of small molecule epilepsy drugs, and they follow our history of successful partnerships with large pharmaceutical companies. “

Under the terms of the deal, AstraZeneca will receive an upfront payment of $ 5 million in cash and $ 7.5 million in Ovid common stock. AstraZeneca is eligible to receive potential clinical development milestones of up to $ 8 million and regulatory milestones of up to $ 45 million. Total commercial milestones could reach $ 150 million and installment royalty payments range from 10% on net sales. At the time of proof of clinical efficacy, AstraZeneca will have the right of first negotiation to opt for a strategic collaboration.

“Ovid’s focus in neuroscience and his experience in the development of novel antiepileptics make him an optimal choice for advancing KCC2 activators, including OV350,” noted Iain Chessell, Global Head of Neuroscience, BioPharmaceuticals R&D, AstraZeneca. “This transaction continues to align development resources with our stated areas of strategic interest. “

OV350 is an early stage compound that has shown encouraging in vitro and in vivo proof of concept in resistant forms of epilepsy. The compound is designed to directly target and activate KCC2, a potassium chloride co-transporter responsible for maintaining chloride homeostasis in neurons. By enhancing chloride homeostasis, OV350 is believed to inhibit neuronal hyperexcitability commonly associated with epilepsies. Research has shown that the presence of mutations and dysfunctions in KCC2 may contribute to the neuronal hyperexcitability commonly seen in epilepsies.1,2

The program was advanced through a collaboration between AstraZeneca and the Tufts Laboratory for Basic and Translational Neuroscience Research, which included Drs. Stephen Moss and Jamie Maguire. Ovid plans to continue a strategic collaboration with Drs. Moss and Maguire, who are leading authorities in GABA receptor research and neuropharmacology. Their associate, Dr Aaron Goldman of Harvard Medical School, will also collaborate with Ovid and translate his expertise in epilepsy drug resistance and the company’s targeted neurotherapy candidates.

“Despite therapeutic advances in recent decades, around one-third to half of people treated for epilepsy continue to have seizures.3,4,5 Therapies that activate KCC2, such as OV350, could become a powerful weapon for clinicians seeking to treat a potential underlying cause of epilepsies, ”according to Dr. Moss.

OV350 extends Ovid’s franchise of new anti-epileptic drugs. The Company is also developing OV329, a next-generation pregabalin for tuberous sclerosis and infantile spasms, which is expected to enter clinical trials in 2022. Earlier this year, Ovid cleared soticlestat, a new cholesterol 24-hydroxylase inhibitor, to Takeda . Soticlestat is currently being investigated in phase 3 trials for Dravet and Lennox Gastaut syndromes.

About the OV350
OV350 is a small molecule that directly activates the KCC2 transporter, which is important for seizure control. In vivo studies have shown that KCC2 activity results in reduced seizure susceptibility and seizure-induced mortality. Preclinical mechanistic studies also demonstrated that OV350 was well tolerated and did not induce sedation. OV350 has the potential to be developed for multiple epilepsies and other CNS indications, including neurodevelopmental and neurodegenerative diseases.

About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company that uses its BoldMedicine® approach to develop drugs that transform the lives of patients with neurological disorders. Ovid seeks to combine deep CNS experience with emerging advances in genetics and brain pathways to create a leading next-generation neuroscience pipeline. Ovid’s current pipeline programs include: OV329, a small molecule GABA aminotransferase inhibitor for seizures associated with tuberous sclerosis and infantile spasms; OV882, a short hairpin RNA therapy approach for Angelman syndrome; OV815, a gene therapy approach for neurological disorders associated with KIF1A; and other research targets. Additionally, Ovid retains a significant financial interest in the future regulatory development and potential commercialization of soticlestat, which Takeda is responsible for advancing globally. Two phase 3 trials for soticlestat in Dravet syndrome and Lennox-Gastaut syndrome are actively recruiting patients. For more information about Ovid, please visit

Forward-looking statements
This press release includes certain disclosures that contain “forward-looking statements” including, without limitation, statements regarding the development and acceleration of Ovid’s product candidate pipeline, Ovid’s strategic approach and business development intentions and opportunities and the ability to derive the desired benefits, Ovid’s ability to identify acquisition targets, potential therapeutic benefits of Ovid’s current or future product candidates, clinical and regulatory development and the potential commercialization of soticlestat, OV329, OV350 or any of Ovid’s current or future product candidates, and Ovid’s eligibility for potential milestone and royalty payments. You can identify forward-looking statements because they contain words such as “will”, “appears”, “believes” and “expects”. Forward-looking statements are based on Ovid’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to uncertainties, risks and inherent changes in circumstances which may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. . Important factors that could cause actual results to differ materially from forward-looking statements include, but are not limited to, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, risks related to the ability to ” Ovid to achieve its financial goals, the risk that Ovid may not be able to realize the expected benefits of its technology, the risks associated with Ovid’s ability to identify acquisition targets or strategic partners, to conclude strategic transactions on favorable terms, or to consume and realize the benefits of any strategic transaction or acquisition and the risks to Ovid or Takeda’s ability to meet the expected timelines and milestones presented by the COVID-19 pandemic In progress. Additional risks that could cause actual results to differ materially from those of forward-looking statements are set out under “Risk Factors” in Ovid’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ( SEC) on November 10. , 2021, and in future filings that Ovid will make with the SEC. All forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether as a result of new information, future events, changes in circumstances or otherwise, unless otherwise required by law.


1 Ellender, TJ, Raimondo, JV, Irkle, A., Lamsa, KP and Akerman, CJ (2014). the excitatory effects of parvalbumin-expressing interneurons maintain epileptiform activity of the hippocampus via synchronous discharges afterwards. J. Neurosks. 34, 15208-15222. doi: 10.1523 / JNEUROSCI.1747-14.2014
2 Magloire, V., Cornford, J., Lieb, A., Kullmann, DM and Pavlov, I. (2019). Overexpression of KCC2 prevents the paradoxical action of promoting seizures of somatic inhibition. Nat. Commmon. 10: 1225. doi: 10.1038 / s41467-019-08933-4
3 Kwan, P., and Brodie, MJ (2000). Early identification of refractory epilepsy. N. Engl. J. Med. 342, 314-319. doi: 10.1056 / NEJM200002033420503
4Shorvon, S., and Luciano, AL (2007). Prognosis of chronic and newly diagnosed epilepsy: revisiting the temporal aspects. Course. Opinion. Neurol. 20, 208-212. doi: 10.1097 / wco.0b013e3280555175
5 Cascino, GD (2008). When drugs and surgery don’t work. Epilepsy 49, 79-84. doi: 10.1111 / j.1528-1167.2008.01930.x


Investors and media:
Ovid Therapeutics Inc.
Meg Alexander


Argot Partners
Dawn Schottlandt

Main logo

The worst offenders in art know fair and late judgment Fri, 31 Dec 2021 14:01:04 +0000

Last month, the Manhattan District Attorney’s Office struck yet another blow against the bad actors who exploit the American art market. Their latest success highlights a lingering weakness in the multibillion-dollar industry: Self-regulation and voluntary policing have not worked. No bad publicity or civil fines. Criminal investigations and legal consequences are needed to stop the trade in illicit antiquities.

On December 6, following a three-year grand jury investigation, Manhattan District Attorney Cy Vance, Jr. announced the seizure of $ 70 million worth of looted antiques from Michael H Steinhardt. The hedge fund titan escaped charges but was sentenced to life in prison in other ways. To avoid prosecution, Steinhardt agreed to a permanent ban on collecting ancient art, the first of its kind.

This unprecedented step, described as “a deferred prosecution agreement, ”Can be more effective than a conviction. This should eliminate a big buyer of illicit antiques from the market forever. This is no small feat, because repeated litigation and scandals since the 1990s have failed to curb what Vance has described as “the billionaire’s rapacious appetite for looted artifacts.”

This news came closely in the wake of other major criminal cases. First, in September, art dealer Nancy Wiener pleaded guilty to three counts of trafficking millions of dollars in antiques. Then, in October, “research adventurer” Douglas Latchford made headlines on several continents for his prolific career as a smuggler. While Latchford died fighting extradition to the United States in 2020, the Pandora Papers opened the box of his crimes, illustrating how he hid millions of dollars from decades of looting through the misuse of tax havens, trusts and offshore accounts. The federal government has made it clear that its investigation of him and his associates is “ongoing.”

The unmasking of Latchford, Wiener and Steinhardt is a reminder that the $ 50.1 billion art market remains the largest unregulated industry in the world. After all, they weren’t street vendors, they were perched at the top of the cultural scene. Steinhardt (still) has a gallery named after him at the Metropolitan Museum of Art. Wiener, and her mother before her, boasted of clients such as Jacqueline Kennedy, John D. Rockefeller III, and Igor Stravinsky. Sir Latchford, pre-charge, has been feted by royalty in Europe and Asia.

Yet all three weren’t content with making regrettable purchases. They knowingly, willfully, and concretely linked themselves to some of the worst humanitarian conflicts and tragedies of the past half a century – from the Killing Fields in Cambodia and the Swat Valley to Pakistan to Lebanon, to Iraq and others. hot spots of the world where there are armed insurgents and violent extremists. known to profit from illicit trade. Relying on false papers and their then sterling reputation, they have successfully laundered countless “blood antiques” and other stolen goods from the legitimate market. Their names frequently echoed in auction blocks at Christie’s and Sotheby’s. And they have sold or donated works to the world’s greatest museums, including the Met, the British Museum, and the National Gallery of Australia.

While some of these institutions may have been genuinely defrauded, most should have known. They are global art leaders with entire departments of lawyers and academics to ensure their acquisitions are legal and ethical. But despite their degrees and other resources, despite red flag after red flag, they continued to accept coins, with few (if any) questions asked.

Such willful blindness has allowed cultural racketeering to become a major global crime. It is difficult to quantify the damage, but Steinhardt alone is known to have purchased more than 1,000 antiques, now valued at $ 400 million. In a related case, authorities recovered more than $ 143 million worth of antiques looted just from the Manhattan properties of art dealer Subhash Kapoor. This is in addition to an additional $ 50 million in illicit artifacts seized from others in New York City since 2017.

Compare that to bank robbery – across the United States thieves only run away with about $ 30 million every year, starting in 2015. Those captured are severely prosecuted with high conviction rates. However, for art and antiques, criminal cases against even prolific delinquents like Steinhardt, Wiener, Latchford and Kapoor are by far the exception, not the rule.

In what industry, other than art, can you search for stolen goods worth hundreds of millions of dollars, or even directly arrange their theft, then expect praise and not prosecution if you return them? ? Looting is a crime. Trafficking is a crime. Possession of stolen goods is a crime. If you commit or facilitate any of these offenses, you should be held accountable. You not only deserve to lose the trust of the public, but also to become the focus of our justice system.

Recent revelations have given the art market and museums an unprecedented opportunity to step up, right past wrongs, and be part of the solution, not the problem. So far, most have failed to take it. Hopefully, the United States and other governments have taken note of this in turn – the only way to fight cultural racketeering in the future is to treat cultural racketeers like the criminals they are.

Deborah Lehr is President and Co-Founder of Antiquities Coalition and CEO of Edelman Global Advisory.

Whole-plant cannabis linked to sharp reduction in seizures Wed, 29 Dec 2021 21:31:49 +0000

Early research shows whole-plant cannabis is linked to a significant reduction in seizures in children with severe treatment-resistant epilepsy.

In a small series of cases, children with severe treatment-resistant epilepsy treated with a range of cannabis-based medicinal products (CBMP) made from whole plant extracts reported an 86% reduction in monthly seizures.

All participants had no improvement with traditional antiepileptic drugs (AEDs).

The study adds to a small but growing body of research looking at whole herbal cannabis medicines containing tetrahydrocannabinol (THC) in pediatric epilepsies.

Rayyan raja zafar

“Although we have already noted the superior efficacy of whole herbal medical cannabis in a previous group of children, it is remarkable that the treatment effect resulted in an average 86% reduction in seizures. epilepsy and demonstrates the obvious clinical value of this product. intervention, “said lead author Rayyan Raja Zafar, a doctoral candidate at the Center for Psychedelic Research and Neuropsychopharmacology at Imperial College London, UK. Medscape Medical News.

The results were published online Dec. 14 in BMJ Paediatrics Open.

Superior to CBD?

The retrospective case series included 10 children under the age of 18 who were recruited by MedCann Support and End Our Pain, charities that represent children who use medical cannabis to treat incurable epilepsies. The data was collected from the parents or caregivers of the patients between January and May 2021.

Patients had a range of epilepsy etiologies and reported a mean of 7 (± 4.58) AED before the onset of CBMP. Two patients showed no improvement in their symptoms after taking Epidyolex, a purified cannabidiol (CBD) approved by the European Commission in 2019 for the treatment of rare forms of epilepsy. The formulation was approved by the United States Food and Drug Administration in 2018 as Epidiolex.

All participants received CBMPs including Bedrolite (<1% THC and 9% CBD), Bedica (14% THC and <1% CBD), Celixir 20 (<1% THC and 20% CBD), Sweet Pink CBD (<1% THC and 10.6% CBD) and Althea 100 (<1% THC and 10% CBD). The drugs were prescribed to patients by clinicians at the National Health Service or by private medical offices.

Patients consumed an average of 5.15 (± 6.8) mg of THC per day and an average of 171.8 (± 153.3) mg of CBD per day.

All patients reported fewer seizures, ranging from a decrease in monthly seizure activity from 62.5% to 100%. The average drop was 86%.

“It appears that whole plant cannabis is superior to CBD alone, and the reasons are speculative,” Zafar said.

“We know that THC has independent antiepileptic activity; however, much less is known about the role that other cannabinoids and minor terpenes play in the cannabis plant, ”Zafar added.

“There have been preclinical tests to suggest that they also have anti-epileptic activity, and therefore the combined effects of the whole plant products appear to work better than a single isolate.”

Selection bias?

Commenting on the findings of Medscape Medical News, Tyler Allison, MD, associate professor of pediatrics at Children’s Mercy Kansas City, Missouri, noted that researchers chose patients based on their long-standing use of whole herbal medicinal cannabis oils, introducing a bias in selection.

“The answer is always interesting, and I think it needs to be investigated further with better parameters in place to reduce bias, but I don’t think it is fair to assess the magnitude of the decrease in seizure frequency when the study population consisted only of patients who responded to treatment, ”said Allison, who was not involved in the research.

“How many patients have tried whole plant cannabis oil and found it not to be effective or at least more effective than their other anti-epileptic drugs?” ” He asked. “This information is missing and could have a significant impact on the importance of the study.”

Selection bias and the small study group also make it difficult to compare the results with previous studies of isolated CBD involving larger patient populations, Allison added.

An intention-to-treat randomized study comparing a control group treated with one form of isolated CBD product and a second group given whole plant cannabis oils would eliminate this bias, he noted. “Then they could analyze seizure frequency the same way they did and compare between groups to see if whole plant cannabis oil shows a reduction in seizure frequency compared to a drug. similar, ”he said.

It’s a design that Zafar noted that he and his colleagues are interested in pursuing.

“We are starting research to better understand the role of cannabinoids and minor terpenes in the treatment of this disease because we want to better understand why we are seeing a superior clinical effect in whole herbal medicines,” he said. declared.

He added that they also plan to partner with academic and business collaborators for additional retrospective and forward-looking studies on these issues.

The study was not funded. Zafar did not report any relevant financial relationships. Disclosures for other authors are listed in the original article. Allison does not report any relevant conflict of interest.

BMJ Paediatr Open. Published online December 14, 2021. Full text

For more information on Medscape Neurology, join us on Facebook and Twitter.

Candace Owens tells fans to take colloidal silver, a quack remedy that makes skin blue Mon, 27 Dec 2021 22:21:30 +0000

Right-wing personality Candace Owens urges her fans to consume a medical quack remedy known to turn users’ skin blue.

In an Instagram video posted Thursday, Owens praised the use of colloidal silver as a daily supplement, a treatment without valid medical use and with many health risks.

“Yes, colloidal silver! Owens said in the video. “I take colloidal silver everyday, love colloidal silver. It’s a big one. It’s another topic that people probably don’t know anything about.

While Owens and others have praised the preventative use of colloidal silver as a means of preventing disease, colloidal silver has no valid medical purpose and has many potential dangers. In extreme cases, according to the Mayo Clinic, colloidal silver can cause seizures or organ problems.

Owens did not respond to a request for comment.

But the most famous side effect of colloidal silver is argyria, a condition that gives users a bluish-gray color, usually permanently. Despite these risks, colloidal silver has occasionally been adopted by political outsiders, including some libertarians seeking cures for various ailments outside the medical system. Montana libertarian politician Stan Jones, for example, turned his skin blue by consuming colloidal silver.

Owens introduced her colloidal silver diet in a follow-up Instagram comment to a fan asking for more information on colloidal silver, saying she takes a “teaspoon a day” and “more when I’m sick” in an article first highlighted by liberal activist William LeGate.

A single teaspoon of silver per day might be enough to cause argyria, depending on the concentration of the silver solution. According to medical research, a 56-year-old man who took a teaspoon daily for “allergy and cold medicine” noticed his fingernails turning blue.

Owens isn’t the only far-right figure to support money as a fringe medicine. In 2020, the FDA warned InfoWars chief Alex Jones to stop promising that silver toothpaste and other silver products sold on its website could prevent or treat the coronavirus.

Owens’ pro-colloidal film video came days after a disastrous interview where Owens, who works for Conservative commentator Ben Shapiro’s Daily Wire, interviewed former President Donald Trump. In a surprise move, Trump brushed aside Owens’ criticism of the coronavirus vaccines, praising the vaccine results as “very good.”

In the same video she praised colloidal silver in, Owens downplayed Trump’s support for vaccines, saying Trump is “too old” to read anti-vaccine information on the internet. She also attacked vaccinations more broadly, claiming, among other things, that there is a “real evil” behind tetanus vaccines.

Staffie undergoes ‘miracle’ operation after eating six packets of chocolate coins Sun, 26 Dec 2021 02:45:00 +0000

A Staffordshire bull terrier has undergone life-saving surgery after gobbling up six packets of Christmas chocolate coins.

Six-year-old pet owner Hugo had been to shops to return to find all their chocolate was gone and wrappers were littering the floor of their home in Plymouth, Devon.

The Staffie was rushed to the town’s PDSA pet hospital where vets made the decision to operate, as chocolate can be fatal to dogs with foil being an added danger .

He was very lucky and could have died if he hadn’t been treated in time. Although not yet fully out of the woods, luckily Hugo is now home with strict rest and on the road to recovery.Donna Southwould, PDSA Pet Nurse

Owner Amie said the PDSA treatment was a “Christmas miracle” for Hugo, adding: “I had only been to the stores briefly and came back to find torn packages and pieces of foil everywhere. on the floor, without chocolate.

“At first Hugo seemed to be fine, but I felt very worried when he started to vomit blood. He then had a seizure which was terrifying, so I called PDSA immediately.

At the hospital run by the veterinary charity, Hugo was assessed, sedated and had an x-ray, which revealed his stomach was full of aluminum foil, requiring surgery to remove it.

PDSA veterinarian nurse Donna Southwould said: “Hugo was kept overnight after his major surgery. He needed a drip of intravenous fluid, medication, and intensive nursing care to help him recover.

“He was very lucky and could have died if he hadn’t been treated in time. Although not fully out of the woods yet, luckily Hugo is now home with strict rest and on the road to recovery. “

Advising owners to be aware of the dangers of festive treats to their pets, she added: Some of these foods are very harmful to our pets.


Packaging films removed from Hugo (PDSA / PA)

“Foods such as chocolate, tarts, onions, raisins, raisins, some nuts, sage and onion stuffing, and Christmas cake can all be harmful and should be kept out of reach. paws.

“Instead of extra food, why not try giving your pets some extra play time this Christmas?”

Amie added, “I don’t know what I would have done without the incredibly kind and caring staff at PDSA – they were amazing. Honestly, I don’t think Hugo would be here without them.

“They went above and beyond for him and I will be eternally grateful to them. There were a number of times I thought we were going to lose it, so having it home for Christmas is a miracle.

A PDSA spokesperson said: “If you think your pet may have eaten something they shouldn’t, call your vet immediately as they may need urgent treatment.”

MDMA, the drug used in ecstasy, may help treat post-traumatic stress disorder Thu, 23 Dec 2021 16:00:00 +0000

For people with post-traumatic stress disorder, recalling memories of physical or sexual assault, fighting, or disaster-related events can cause intense anxiety or panic attacks as well as debilitating flashbacks. .

In the United States, about 7% of people suffer from PTSD and lose an average of about four days of work each month. Trauma-specific psychotherapy, such as cognitive therapy or talk therapy, is the cornerstone of treatment for the disorder. But for about half of people, these traditional approaches are ineffective in fully treating long-term symptoms. Antidepressants are frequently used when psychotherapy has failed, or in combination with it, but the effects are usually modest.

MDMA (3,4-methylenedioxymethamphetamine) is an active ingredient in the illicit street drug known as ecstasy or molly. People at dance clubs and raves consume illicit MDMA because it elevates mood and energy levels, induces a sense of connection with others, and produces a surreal psychedelic high.

These same effects have been hypothesized to support people with PTSD during psychotherapy sessions because they can make people more willing and able to share and explore their traumatic experiences. Our new clinical trial meta-analysis confirms the benefits of MDMA-assisted psychotherapy in the treatment of PTSD.

We are a team of pharmacists and physicians who investigate the pros and cons of drugs of abuse like bath salts, phenibut, cannabis, and synthetic marijuana. Through this work, we have been intrigued by the therapeutic potential of certain psychedelic drugs in the treatment of a myriad of psychiatric disorders, from PTSD to major depression, in particular MDMA and psilocybin (hallucinogenic mushrooms).

It is important to clarify that the use of ecstasy or street molly products would not help the symptoms of PTSD, as MDMA must be used with carefully designed psychotherapy in a safe and controlled environment. Illegally purchased ecstasy or molly products never state the exact amount of MDMA they contain, so it is impossible to dose it correctly for PTSD. Taking too much MDMA or exercising while taking MDMA can cause heart attacks, strokes, seizures, and arrhythmias, and can damage muscles and kidneys.

MDMA-assisted psychotherapy

In an MDMA-assisted psychotherapy session, patients take MDMA in pill form upon entering a psychiatrist’s office, then work with a team of therapists who help them disclose traumatic events or discuss aspects. of these events for several hours. They usually have non-MDMA sessions before the first MDMA session so they know what to expect.

And they have at least one non-MDMA session after each MDMA session to work on the traumatic memories that have been revealed and to learn coping strategies. A standard course of treatment consists of two or three sessions of MDMA-assisted psychotherapy lasting several hours and several sessions without MDMA.

The MDMA products used in these sessions are pharmaceutical grade. This means that, unlike illegally obtained street foods, they do not contain other substances of abuse, such as methamphetamine, or contaminants such as heavy metals, bacteria or mold. People with hypertension or those at high risk of heart attack, stroke, or arrhythmia should not participate, as they can have dangerous elevations in blood pressure and heart rate. Additionally, patients are not allowed to go outside for eight hours, until the effects of MDMA have worn off completely.

MDMA crystals. Photo credit: Thawt Hawthje / Wikimedia Commons (CC BY 2.0)

Evaluate the effectiveness

In 2014, we looked at the available animal data and the few preliminary human studies of MDMA-assisted psychotherapy, but at the time, the higher-quality clinical trials were not yet complete. But in recent years, larger and better trials have emerged that warrant further evaluation.

So we recently reviewed data comparing the use of antidepressants versus placebos for patients with PTSD and performed a meta-analysis of six different clinical trials that assessed the usefulness of MDMA-assisted psychotherapy versus psychotherapy alone. All of the trials we analyzed included both men and women who had experienced a multitude of traumatic events leading to PTSD.

The studies used the same point scale to determine the effectiveness of treatment, making it easier to compare data between studies. Scores greater than about 50 points mean that a patient has severe PTSD, and scores reduced by more than 10 points from baseline are clinically significant.

We found that daily antidepressant treatment reduced PTSD by six to 14 points compared to placebo, but a range of 27% to 47% of patients in the studies withdrew before the end of the trials.

In contrast, MDMA-assisted psychotherapy reduced scores by 22 points compared to those receiving psychotherapy with placebo, and patients were twice as likely to no longer meet diagnostic criteria for PTSD at the end of the trials. In addition, only 8% of patients withdrew from MDMA-assisted psychotherapy trials.

The main side effects included teeth grinding, nervousness, headache and nausea. One of these MDMA trials found that participants’ blood pressure and heart rate were elevated during MDMA treatment, but not to any level of concern.

For several of the trials in our meta-analysis, investigators sent participants a questionnaire 12 months after their last MDMA session to assess the long-term impact. Overall, 86% of participants reported receiving substantial benefits from MDMA-assisted combination psychotherapy.

Eighty-four percent of participants said they improved their sense of well-being, 71% had fewer nightmares, 69% had less anxiety, and 66% had better sleep. The results of all the studies suggested that MDMA-assisted therapy helped relieve the PTSD itself, not just suppress the symptoms.

Look ahead

The United States Drug Enforcement Administration identifies MDMA and psilocybin as Schedule I controlled substances. According to the Drug Enforcement Administration, these substances currently have no accepted medical use in the United States and have the potential to high abuse.

However, an important exception should be noted. Cannabidiol, or CBD, a chemical that comes from the plant Cannabis sativa, is classified as a Schedule I drug. But the Food and Drug Administration approved its use in 2018 for the treatment of two rare and serious seizure disorders in children. This doesn’t mean that the CBD in your lotion or seltzer has beneficial effects on most of the ailments people use it for, but its full therapeutic potential is still under investigation. Given the strong and consistent beneficial effects and manageable adverse events in the new trials designed with input from the FDA, we suspect that MDMA-assisted psychotherapy will become an FDA-approved option for PTSD by the end of 2023. Psilocybin – commonly known as hallucinogenic mushrooms – also has shown promise for the treatment of major depression, but more research is needed.

Strict Drug Enforcement Administration policies have made it exceptionally difficult for scientists to conduct research on Schedule I drugs for decades by criminalizing possession of the products, even in the course of research.

But in 2018, the agency streamlined the application process for a research waiver. This made it easier for researchers to conduct trials on the pharmaceutical value of psychedelic drugs. Over the next decade, this change will almost certainly accelerate the discovery of new treatments for patients with mental illness.

C Michael White is Distinguishedhed professor and head of the pharmacy practice department and Adrian V Hernandez is Associate Professor of Comparative Efficacy and Outcome Research at the University of Connecticut.

This article first appeared on The Conversation.